Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: Potential for targeted therapy

Pathology

Volumn 44, Issue 5, 2012, Pages 453-459

  Rajandram, Retnagowri ^a,e   Bennett, Nigel C ^a   Wang, Zhiqiang ^b   Perry Keene, Joanna ^c   Vesey, David A ^a,d   Johnson, David W ^a,d   Gobe, Glenda C ^a,b  

^a Centre for Kidney Disease Research   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Apoptosis; Molecular marker; Renal cell carcinoma; SiRNA; TRAF; Tumour necrosis factor

Indexed keywords

ALPHA INTERFERON; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

APOPTOSIS; CELL PROLIFERATION; CONFERENCE PAPER; GENE SILENCING; GENETICS; HUMAN; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MITOSIS; PATHOLOGY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERFERON-ALPHA; KIDNEY; KIDNEY NEOPLASMS; MITOSIS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TNF RECEPTOR-ASSOCIATED FACTOR 1;

EID: 84866899499     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283557748     Document Type: Article

References (34)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organisation Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004; 12-31.
2. Sfoungaristos S, Giannitsas K, Perimenis P. Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma. Expert Opin Pharmacother 2001; 12: 533-47.
3. Gobe G, Rubin M, Williams G, Sawczuk I, Buttyan R. Apoptosis and expression of Bcl-2, Bcl-X-L, and Bax in renal cell carcinomas. Cancer Invest 2002; 20: 324-32.
4. Davidson K, Percy C, Rennick AJ, et al. Comparative analysis of caspase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas. Nephron Exp Nephrol 2005; 99: E112-20.
5. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence. Oncologist 2001; 16 (Suppl 2): 14-22.
6. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-30.
7. Izban KF, Alkan S, Singleton TP, Hsi ED. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21(WAF1), p27(KIP1), and p53 in mantle cell lymphoma. Archiv Pathol Lab Med 2000; 124: 1457-62.
8. Zapata JM, Llobet D, Krajewska M, Lefebvre S, Kress CL, Reed JC. Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood 2009; 113: 4595-603.
9. Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF. NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 2007; 110: 743-51.
10. Rajandram R, Pat BK, Li J, Johnson DW, Gobe GC. Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma. Nephrology (Carlton) 2009; 14: 205-12.
11. Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family-Scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 2001; 13: 389-400.
12. Hauer J, Puschner S, Ramakrishnan P, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005; 102: 2874-9.
13. Lavorgna A, De Filippi R, Formisano S, Leonardi A. TNF receptorassociated factor 1 is a positive regulator of the NF-kappaB alternative pathway. Mol Immunol 2009; 46: 3278-82.
14. Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002; 115: 679-88.
15. Sabbagh L, Srokowski CC, Pulle G, et al. A critical role for TNF receptorassociated factor 1 and Bim down-regulation in CD8 memory T cell survival. Proc Natl Acad Sci USA 2006; 103: 18703-8.
16. Tsitsikov EN, Laouini D, Dunn IF, et al. TRAF1 is a negative regulator of TNF signaling: Enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001; 15: 647-57.
17. Chaudhary PM, Eby MT, Jasmin A, Kumar A, Liu L, Hood L. Activation of the NF-kappaB pathway by caspase 8 and its homologs. Oncogene 2000; 19: 4451-60.
18. Irmler M, Steiner V, Ruegg C, Wajant H, Tschopp J. Caspase-induced inactivation of the anti-apoptotic TRAF1 during Fas ligand-mediated apoptosis. FEBS Lett 2000; 468: 129-33.
19. Jang HD, Chung YM, Baik JH, et al. Caspase-cleaved TRAF1 negatively regulates the antiapoptotic signals of TRAF2 during TNF-induced cell death. Biochem Biophys Res Commun 2001; 281: 499-505.
20. Leo E, Deveraux QL, Buchholtz C, et al. TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis. J Biol Chem 2001; 276: 8087-93.
21. Henkler F, Baumann B, Fotin-Mleczek M, et al. Caspase-mediated cleavage converts the tumor necrosis factor (TNF) receptor-associated factor (TRAF)-1 from a selective modulator of TNF receptor signaling to a general inhibitor of NF-kappaB activation. J Biol Chem 2003; 278: 29216-30.
22. Iatropoulos MJ, Williams GM. Proliferation markers. Exp Toxicol Pathol 1996; 48: 175-81.
23. Li J, Vesey DA, Johnson DW, Gobe G. Erythropoietin reduces cisplatininduced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther 2007; 6: 1944-50.
24. Hughes J, Gobe G. Identification and quantification of apoptosis in the kidney using morphology, biochemical and molecular markers. Nephrology (Carlton) 2007; 12: 452-8.
25. Kerr JF, Gobe GC, Winterford CM, Harmon BV. Anatomical methods in cell death. Methods Cell Biol 1995; 46: 1-27.
26. Liotta LA, Kohn E. Anoikis: Cancer and the homeless cell. Nature 2004; 430: 973-4.
27. Lei Y, Geng Z, Guo-Jun W, He W, Jian-Lin Y. Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol Cell Biochem 2010; 344: 23-31.
28. Sturm I, Stephan C, Gillissen B, et al. Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ 2006; 13: 619-27.
29. Zapata JM, Lefebvre S, Reed JC. Targeting TRAFs for therapeutic intervention. Adv Exp Med Biol 2007; 597: 188-201.
30. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001; 20: 6482-91.
31. Rothe M, Xiong J, Shu HB,Williamson K, Goddard A, GoeddelDV. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc Natl Acad Sci USA 1996; 93: 8241-6.
32. Lipponen P, Eskelinen M, Syrjanen K. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 1995; 71: 863-7.
33. Wu XX, Kakehi Y, Mizutani Y, Lu J, Terachi T, Ogawa O. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 2001; 19: 19-24.
34. Ramp U, Caliskan E, Mahotka C, et al. Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. Br J Cancer 2003; 88: 1800-7.